Categories: News

Ocugen to Host Conference Call on Friday, February 25 at 8:30 a.m. ET to Discuss Fourth Quarter and Full Year 2021 Financial Results and Provide Business Update

MALVERN, Pa., Feb. 18, 2022 (GLOBE NEWSWIRE) — Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that it will host a conference call to discuss its fourth quarter and full year 2021 financial results and provide a business update at 8:30 a.m. ET on Friday, February 25, 2022.

Ocugen will issue a pre-market earnings announcement on the same day. Investors are invited to participate on the call using the following details:

About Ocugen, Inc.
Ocugen, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug – “one to many” and our novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema and diabetic retinopathy. We are co-developing Bharat Biotech’s COVAXIN™ vaccine candidate for COVID-19 in the U.S. and Canadian markets. For more information, please visit www.ocugen.com.

Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. Such forward-looking statements within this press release include, without limitation, the intended use of net proceeds from the registered direct offering. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from our current expectations, such as market and other conditions. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (the “SEC”), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events or otherwise, after the date of this press release.

Ocugen Contact:
Ken Inchausti
Head, Investor Relations & Communications
IR@Ocugen.com

Please submit investor-related inquiries to: IR@ocugen.com

Staff

Recent Posts

Simplifying Subcutaneous Drug Administration: SCHOTT Pharma and KORU Medical Systems Announce Collaboration to Advance Large Volume Subcutaneous Infusion

The companies, KORU Medical, manufacturer of the proprietary, large-volume, Freedom Infusion System (the “Freedom System”)…

2 hours ago

Simplifying Subcutaneous Drug Administration: SCHOTT Pharma and KORU Medical Systems Announce Collaboration to Advance Large Volume Subcutaneous Infusion

The companies, KORU Medical, manufacturer of the proprietary, large-volume, Freedom Infusion System (the “Freedom System”)…

2 hours ago

Masimo Joins Forces with the Mobilize Recovery 2024 Bus Tour

Collaborative Partnership Designed to Enhance Nationwide Efforts to Combat the Opioid Epidemic and Improve Addiction…

2 hours ago

KindlyMD Becomes First Utah Alternative Medical Treatment Company to Contract Under State’s Top Insurance Payors

Insurance payors include Medicare, Utah's largest insurer, Select Health, and Medicaid, providing KindlyMD nearly 70%…

2 hours ago

Applied DNA Announces Notice of Allowance for U.S. Patent Covering Fundamental Aspect of its Linea(TM) IVT Platform

Patent covers the Composition of the Company's Proprietary Linea™ RNAP, a Core Technology Empowering the…

2 hours ago

Inspire Names Health Tech Leader Brett Kleger as New CEO

ARLINGTON, VA / ACCESSWIRE / June 5, 2024 / Inspire, the world's leading online health…

2 hours ago